Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leritrelvir PK in severe kidney impairment
NCT06160622Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Covalent Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of leritrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum observed plasma concentration and Area under the concentration-time curve from time zero to last time of quantifiable concentration. Started Sep 2023; status: completed.
02
Drugs
leritrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06160622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160622.